Patrick Dorr

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

Patrick Dorr, Mike Westby, Susan Dobbs et al. · Antimicrobial Agents and Chemotherapy · 2005 · 1.1K citations

Medicine, Medicinal Chemistry, Pharmacology +17

Reduced Maximal Inhibition in Phenotypic Susceptibility Assays Indicates that Viral Strains Resistant to the CCR5 Antagonist Maraviroc Utilize Inhibitor-Bound Receptor for Entry

Mike Westby, Caroline Smith‐Burchnell, Julie Mori et al. · Journal of Virology · 2006 · 346 citations

Life Sciences, Microbiology, Pharmacology +17

Novel Small-Molecule Inhibitors of RNA Polymerase III

Liping Wu, Jing Pan, Vala Thoroddsen et al. · Eukaryotic Cell · 2003 · 88 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +15

Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 Pneumonia

Jane A. O’Halloran, Emily R. Ko, Kevin J. Anstrom et al. · JAMA · 2023 · 67 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +11

Cyanide oxygenase and cyanase activities of<i>Pseudomonas fluorescens</i>NCIMB 11764

Patrick Dorr, Christopher J. Knowles · FEMS Microbiology Letters · 1989 · 52 citations · Full text

Life Sciences, Biochemistry, Microbiology +8